COMPANY REPORT
VIEW TOP | 3
from the
Q: What makes Within3 a smart solution for virtual engagement and why do stakeholders need it to ensure better treatment development? A: Most pharmaceutical companies meet in person to engage with key stakeholders but travel restrictions imposed during the pandemic led companies to turn to virtual alternatives to interact with their client base. The pandemic also accelerated the use of virtual platforms for internal engagement. COVID-19 made the industry adopt in 24 months what in other circumstances would have taken five to seven years. Thanks to this greater experience with virtual engagement technologies, businesses have recognized that technology adoption is no longer an innovation but a necessity for business continuity. Pharmaceutical and medical devices companies have also embraced virtual engagement technologies when engaging physicians and patients. These actors are spread throughout the country and travel is now difficult, and even dangerous. In urban settings, virtual engagement has been welcomed because of the heavy burden of commuting. Other areas have limited access to good internet connectivity so our software also works via browser. Q: How does Within3 help its clients make fast, agile decisions using insights from key opinion leaders?
Lance Hill
A: We have access to a robust set of data in Mexico and many other countries, which we use to help companies understand how to engage a community. It is all about understanding population
CEO| Within3
needs. Within3’s platform does that with extraordinarily high participation and information. We also help companies organize that information into insights. Instead of delivering a long transcript from a Zoom meeting, we give them an insight with all information explained that saves them weeks. Our insights
Effective Communication Provides RealTime Insight
allow us to analyze interactions in the sector to paint a picture of the most active players on certain topics. We give life science companies a picture of who they might want to interact with. Q: What is the role of Within3 in generating savings in medicine or product developments? A: Pharmaceuticals spend billions of dollars to bring drugs to the market. These costs come from a massive communication problem because there are numerous stakeholders involved at every step of the process, from scientists to economists. Within3 helps companies speed up communication so information is gathered and understood faster, which allows companies to accelerate processes down the line. Q: How does Within3 protect its platform from cyberattacks? A: We invest significantly to make sure that we are strengthening our systems as much as possible. Many clients conduct their own penetration studies at Within3 to assess our environment before they start working with us. Historically, Within3 centered on getting physicians’ online to share information with each other
Read the complete article More about this person More about this company
and with their pharmaceutical or medical device sponsors. We have a new product for the analysis of breast cancer communities to help clients understand what is happening with these patients and to get a better sense of how to answer larger questions, such as where their company locate clinical trial sites.
VIEW TOP | 4
from the
Q: How have trials for Takeda’s dengue vaccine turned out and what is the importance of this development? A: This vaccine has been in clinical development for over five years. The first regulatory submission was just introduced this year and we are looking forward to the results as this vaccine will bring hope and opportunities to the Mexican population. With this vaccine, Takeda is preventing the health complications that arise from hemorrhagic dengue. The company is also seeking to add to the primary care of this disease. At Takeda, we are still working to make the vaccine fully available because we know how much it would mean to Mexico. Mexico will participate in the vaccine’s development through clinical trials, which will allow scientists to observe how the solution affects participants and generate scientific evidence. Q: What role does Takeda want to play in the development of the pharmaceutical industry in Mexico and in the battle against the country’s chronic-degenerative burden? A: Takeda is committed to being one of the most innovative biopharmaceutical companies in the world to address neglected diseases. As a company, we also want to raise awareness about these unknown diseases to avoid future complications that can later lead to chronic degenerative diseases. We want to transform
Estefanía Torres
patients’ lives through awareness, adherence to treatment, support and follow-ups. During the pandemic, we noticed that ambulatory treatments
Therapeutic Area Lead | Takeda
were an active way to keep in touch with our patients and foment the adherence to treatment. Through our ambulatory solutions, patients no longer need to visit hospitals on a weekly basis. Instead, they receive their treatment at home.
Tech as an Ally for Treatment Development, Adherence
At Takeda, we work closely with doctors to offer better solutions that meet the needs of their patients. This work has been carried out through our Within3 platform, which overcomes COVID-19 limitations to offer a digital solution to the R&D areas of pharmaceutical companies. Within3 provides a virtual space to talk with doctors and other relevant stakeholders to generate a continuous, uninterrupted workflow that facilitates innovation. For players in the biopharmaceutical and pharmaceutical industry, constant contact with the medical community, patient groups and management teams is key to developing better solutions for their needs. Technology applications, such as Within3, have accelerated our processes and given us flexibility. As a result, productivity has improved and we are able to use our time more efficiently. Q: How is Takeda enhancing access to its innovative therapies? A: We carry out multidisciplinary efforts. For example, we provide doctors and specialists with continuous information regarding our innovations and their benefits. We also provide educational forums for primary contact doctors, who need to be properly trained to gain a wider perspective of diseases, disease trends and available solutions. This is fundamental for patients to receive a timely
Read the complete article More about this person More about this company
diagnosis through a proper first contact experience. Our medicine access teams are in charge of the regulatory requirements of each country to introduce our therapies to institutions and facilities.
VIEW TOP | 5
from the
Q: What motivated the development of your communication software? A: Our mission is to connect the world of life sciences and healthcare. Investment in technology is mainly focused on big data analytics for better decision-making but there has been very little investment in solving communications problems among the different actors within these two sectors. All companies in life sciences and healthcare need to be in constant communication with their consumers, from payers to physicians. Normally, the way to do this is by hosting a presential or virtual meeting with all these actors together. We transformed this into a virtual platform. Within3 has built a virtual engagement platform that allows life sciences and health companies to bring together all their different stakeholders into an online space that generates engagement by offering a trusted venue to gain deep insight into the marketplace, to collaborate on products or treatments and to co-work on publications, with a spectrum of other activities along the way. Within3 strives for better, faster, cheaper and safer communications networks for our clients. Furthermore, we created a model that allows physicians and patients to help life sciences and health companies bring their treatments to the market. Q: What is the goal of each of Within3’s applications?
Lance Hill
A: That depends on the client’s project. For instance, an R&D project for a pharmaceutical company will require a workspace that allows questions, tracks the workflow of researchers and
CEO | Within3
provides an opportunity for dialogue or interaction so all parties can work together to develop the solution. At the same time, it opens up opportunities for discussion on the subject. For instance, a pharmaceutical company working on a product for the Mexican market would need different insights from
Communication Solution Boosts Health Access
that market. Typically, they would approach a limited number of physicians in the country and consult with them on the treatment and its uses. This is usually time-consuming because you have to align people’s schedules, which also takes time away from the physician’s practice. Even though physicians are now using virtual platforms more often, they are swamped with work and consulting them becomes difficult. Within3 solves all those problems with its virtual venue. The pharmaceutical company can create a space with appropriate parameters to host the content it needs to gather. Physicians can simply upload their inputs to the platform when they have the time to do so. There is no need to try to get everyone together at the same time. The result is a much more diverse, faster and convenient way to engage with stakeholders. Q: How does the platform generate and measure engagement? A: Prior to the pandemic, Within3 was growing at a 100 percent rate. With the imposition of travel restrictions and lockdowns, our impact increased. As people began migrating to the digital world, there was a general assumption that people would
Read the complete article More about this person More about this company
have homogeneous tech access, from internet connections to technological understanding of their platforms. In reality, this is not the case. Instead of forcing stakeholders, physicians, patients and clients to be available at the same time, companies need to be available at the convenience of these actors.